| ||||
News, Publications, and Related Stories
ERBB Receptor Activation Is Required for Profibrotic Responses to Transforming Growth Factor {beta}.
Cancer Research -- Oct. 1, 2010 View Related
Genetic Engineering & Biotechnology News -- Feb. 23, 2010 Alan Fields, Ph.D., and Nicole Murray, Ph.D., have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. View Related
Tehran Times -- Dec. 12, 2009 Lead investigator: Jan van Deursen, Ph.D., Mayo Clinic in Rochester, Minn. View Related 
The Daily Scan, genomeweb.com -- Oct. 26, 2009 Research by Stephen Ekker, Ph.D., et al, regarding genetic differences in response to nicotine, using zebrafish animal model View Abstract 
Discovery's Edge - Mayo Clinic's Research Publication Zebrafish make an ideal model organism for genetic and developmental studies. A molecular biologist at Mayo is not only using the fish to investigate new treatments for cancer and nicotine addiction, but also as the foundation of a paradigm to get students excited about science. View Related 
According to the American Cancer Society, lung cancer is the second most common cancer among both men and women, and the leading cause of cancer death in the United States. "Lung cancer stem cells appear to be the major drivers in many common lung cancers, and in order for a therapeutic treatment to be effective, it has to disrupt these cancer stem cells," says study senior author Alan Fields, Ph.D., professor of pharmacology and chair of the Department of Cancer Biology at Mayo Clinic's campus in Florida. "We show that aurothiomalate, the agent now being tested in lung cancer patients, can, in fact, target these cells." View Related
Cancer Center member Jan van Deursen, Ph.D. was awarded the Vita Valley Professorship in Cellular Senescence. View Related 
Mayo Clinic Cancer Center receives an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center.
Researchers say that a molecule known as protein kinase D1 (PKD1) is key to the ability of a tumor cell to "remodel" its structure, enabling it to migrate and invade. View Abstract
RS5444, being tested in a Phase 1/2 clinical trial to treat anaplastic thyroid cancer, might be useful for treating other cancers. "This is very unusual," says the study's lead investigator, John Copland, Ph.D., a cancer biologist at Mayo Clinic's campus in Florida. "Drugs typically target genes and proteins that are over-expressed and turn them off. We found that RS5444 turns on a valuable tumor suppressor gene. We rarely find a drug that can take a suppressed gene and cause it to be re-expressed." View Abstract 
"There is need for an agent that has a proven ability to reduce colon cancer risk, and this study suggests that enzastaurin could be uniquely effective," says the study's senior investigator, Nicole Murray, Ph.D., of the Department of Cancer Biology. View Abstract 
"An anti-p120 agent could provide a much-needed double whammy — stop cancer spread and shut down growth at the same time," says the study's lead investigator, Panos Anastasiadis, Ph.D., a Mayo Clinic cancer researcher. Available online in the November issue of the Journal of Cell Biology. View Abstract
Publication: The Journal of Cell Biology -- Nov. 17, 2008 
William C. Rupp, M.D., has been appointed CEO for the Florida campus effective Nov. 21, Mayo Clinic announced today. Rupp currently leads quality projects for Luther Midelfort, part of Mayo Health System, as well as Mayo Clinic. 
Mayo Clinic is making big discoveries about minute bits of matter that could revolutionize cancer and heart disease treatment. 
Increased expression of SULF2 enhances cancer cell growth and migration, whereas decreased expression reduces both. Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence. But Mayo Clinic Cancer Center, in collaboration with the National Cancer Institute, reports in the April issue of Hepatology that the protein sulfatase 2 (SULF2) may provide one of the keys needed to begin the design of new therapies. View Abstract 
The research team discovered that women whose atypia tissue expressed COX-2 enzymes were more likely to develop breast cancer subsequently, and that the more the enzyme expressed, the higher the risk. View Abstract
Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related
Discovery's Edge "When we examined human breast tissue we were blown away by how dramatic and obvious the centrosome abnormalities were in the tumors," says Jeffrey Salisbury, Ph.D. "And that was literally on day one." View Related
Publication: Cancer Research -- Sept. 15, 2007
Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related
The National Institutes of Health chose Mayo Clinic as one of the first 12 institutions to receive Clinical and Translational Science Awards (CTSA) in October 2006. "There are two objects in medical education: to heal the sick and advance the science." - Dr. Charles H. Mayo 
Yuan-Ping Pang, Ph.D. established the Computer-Aided Molecular Design Laboratory (CAMDL) to learn more about how biological systems function and to establish models that could lead to new treatments for infectious diseases and cancer. View Related 
Osteoporosis was not even considered a disease before Mayo Clinic's 1980s groundbreaking epidemiology studies. Funded by a $1.2 million per year NIH Program Project grant, the osteoporosis research team is also taking their research to the genetic and molecular levels to study the physiology of bone metabolism in an aging population. Their studies investigate the TGF-beta-Inducible Early Gene (TIEG) gene's role in bone and skeletal disorders such as osteoporosis and breast cancer metastasis to the bone. View Related 
Custom-fitting a Drug for a Child with Leukemia Some 20 years ago, Mayo Clinic researcher Richard Weinshilboum, M.D., and colleagues made a groundbreaking discovery: They determined why a dose of a drug that could produce astonishing cures in a lethal childhood cancer sometimes also could produce side effects that killed children. The reason behind this strikingly individual response to a drug was found in the genes. With this profound insight into the role that a patient's genetic make-up plays in how the patient responds to a drug, the new field of pharmacogenomic medicine was born. It continues to grow today—Mayo Clinic research leading the way discovering new treatment applications that range from depression, to breast cancer, to chemical dependency. View Related
Publication: Cancer Research -- Oct. 15, 2006 Combined deletion of chromosomes 1p and 19q is associated with improved prognosis and responsiveness to therapy in patients with anaplastic oligodendroglioma. Jenkins et al. used stem cell culture techniques to recover a t(1;19)(q10;p10) from an oligodendroglioma, suggesting that the translocation likely mediates the combined 1p and 19q deletions. The authors then developed an interphase fluorescence in situ hybridization (FISH) strategy to detect the t(1;19) in paraffin-embedded tumors. Using gliomas from patients enrolled on NCCTG trials, the FISH test demonstrated that the translocation is highly prevalent in oligodendrogliomas and is associated with superior survival. View Related
Publication: Cancer Research -- Oct. 15, 2006 To understand better the underlying mechanisms by which tumor cells are resistant to CTL-mediated apoptosis, Yang et al. used a human model of B-cell non-Hodgkin’s lymphoma (B-cell NHL) to show that intratumoral Treg cells inhibit the proliferation and granule production of activated autologous infiltrating CD8+ T Cells. View Related
Publication: Science -- Oct. 13, 2006 Biochemistry and Molecular Biology department researchers report that a protein that initiates a “quality control check” during cell division also directs cell death for those cells damaged during duplication. View Related 
The Clinical Research Training Program provides a formal education in all aspects of clinical research, including grant-writing, legal and ethical issues, statistics, epidemiology and study design and protocols. "I realized how exciting research can be, and how exciting it is to advance the science." Jon Ebbert, M.D. View Related 
Publication: Journal of Cell Biology -- Sept. 25, 2006 p120 catenin is a protein known for as a key cell adhesion component. New findings by Mayo Clinic Cancer Center researchers at Jacksonville show that p120 also works to break cells apart from one another and promote cellular movement when tumors metastasize. The study illuminate a very early step involved in metastasis, the spread of cancer that makes the disease difficult to treat, and suggests that a future designer drug might be able to block the beginning of this dangerous process – or stop it once it starts. View Related
Publication: Cancer -- July 1, 2006 Mononuclear cell infiltration is associated with death from renal cell carcinoma even after multivariate adjustment. Routine documentation of mononuclear cell infiltration is recommended during the pathologic assessment of renal cell carcinoma. View Related 
Medical Edge Television One in eight. Those are the odds that your mom, sister, wife or friend has of getting breast cancer in her lifetime. The risk goes way up if you have one of two known breast cancer genes.
In helping young investigators, Mayo Clinic again is connecting all the dots -- leading back to the same point, the same mission, ongoing and yet unchanged for over a century: the needs of the patient come first. New, young investigators are critical to biomedical research. Their fresh ideas, innovativeness, and enthusiasm are necessary for scientific progress. Yet the steps from a junior research position toward a self-sufficient laboratory can be difficult. Mayo Clinic is dedicated to fostering future, investigators. Here we look at two of them and what Mayo is doing to help. View Related
In scientific literature, epidemiologic studies have linked reduced rates of certain cancers to cultures in Asia where green tea is a popular drink. Legend has it that the Chinese Emperor Shen Nung discovered tea around 2737 B.C.E. He was known as the Divine Healer, and that title is almost all one needs to know about why legends, right or wrong, persist. Green tea has come down through the ages, trailing behind it mythic tales of health benefits from "cheering the heart" to reducing inflammation, from improving bladder function to treating tumors. View Related
Renal cell carcinoma is one of most dangerous forms of kidney cancer. An interdisciplinary team of Mayo Clinic investigators and Mayo's Comprehensive Cancer Center are pursuing improved treatments by pooling data and expertise with support from Florida. "With this approach, we can halt the disease and begin to cure kidney cancer." John Copland, M.D. View Related
Mayo Clinic’s Molecular Medicine Program has three gene therapy clinical trials open in which the entire preclinical cycle—concept, discovery of agent, vector manufacture, toxicology and efficacy studies, and new drug application—was conducted at Mayo The projects engineered strains of the measles virus, MV-CEA and MV-NIS, which kill multiple cancer cells, and can be monitored easily. The open trials are in ovarian cancer, glioblastoma multiforme (brain cancer), and multiple myeloma. This article discusses the general research and the first trial which opened -- ovarian cancer. The projects are a fine example of a clear translational effort from bedside to bench and back to the bedside. 
Publication: Journal of Clinical Oncology -- May 1, 2004 North Central Cancer Treatment Group study View Related
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
Publication: Blood -- Oct. 1, 2003 View Related
|
LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE
Use of this site signifies your agreement to the terms of use.
© 2012 Mayo Foundation for Medical Education and Research. All rights reserved.
